Pediatric Abdominal Tuberculosis Treatment Guidelines

Recommended Treatment Regimen

The American Academy of Pediatrics recommends a standard 6-month regimen consisting of rifampin, isoniazid, pyrazinamide, and ethambutol for the initial 2 months, followed by rifampin and isoniazid for 4 months, for the treatment of pediatric abdominal tuberculosis 1

The World Health Organization suggests the four-drug intensive phase includes: isoniazid (10-15 mg/kg/day), rifampin (10-20 mg/kg/day), pyrazinamide (15-30 mg/kg/day), and ethambutol (15-25 mg/kg/day) for the initial 2 months of treatment 2, 1
Ethambutol should be included in all pediatric cases until drug susceptibility results confirm full susceptibility, even in young children where visual monitoring is challenging, as emphasized by the American Academy of Pediatrics 4, 1

The Centers for Disease Control and Prevention recommends continuing with rifampin (10-20 mg/kg/day) and isoniazid (10-15 mg/kg/day) for the remaining 4 months of treatment 1

The American Academy of Pediatrics states that abdominal tuberculosis (intestinal and peritoneal TB) requires only 6 months of treatment, the same as pulmonary TB, with the exception of TB meningitis or CNS involvement, which requires 12 months of treatment 5, 1

The World Health Organization recommends pyridoxine (vitamin B6) supplementation to prevent isoniazid-induced peripheral neuropathy in breast-fed infants, malnourished children, and HIV-infected children 1

The Centers for Disease Control and Prevention strongly recommends directly observed therapy (DOT) throughout the entire treatment course to ensure adherence 1, 6

The World Health Organization suggests that if drug resistance is suspected or confirmed, treatment regimens should be modified, such as using rifampin, pyrazinamide, and ethambutol for 6-12 months for isoniazid-resistant TB, and individualized regimens based on susceptibility testing for MDR-TB 1

The American Academy of Pediatrics recommends baseline visual acuity testing before starting ethambutol, with monthly questioning about visual disturbances at each visit, and obtaining bacteriologic cultures before starting therapy to confirm susceptibility and assess for HIV co-infection 6, 3, 1